DE69233245T2 - Verfahren zur Herstellung von Peptiden - Google Patents
Verfahren zur Herstellung von Peptiden Download PDFInfo
- Publication number
- DE69233245T2 DE69233245T2 DE69233245T DE69233245T DE69233245T2 DE 69233245 T2 DE69233245 T2 DE 69233245T2 DE 69233245 T DE69233245 T DE 69233245T DE 69233245 T DE69233245 T DE 69233245T DE 69233245 T2 DE69233245 T2 DE 69233245T2
- Authority
- DE
- Germany
- Prior art keywords
- peptide
- fusion protein
- target
- linker
- target peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 153
- 238000000034 method Methods 0.000 title claims abstract description 63
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 35
- 238000002360 preparation method Methods 0.000 title description 3
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 152
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 152
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 60
- 210000004027 cell Anatomy 0.000 claims abstract description 40
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 39
- 230000001681 protective effect Effects 0.000 claims abstract description 28
- 102000004190 Enzymes Human genes 0.000 claims abstract description 9
- 108090000790 Enzymes Proteins 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims abstract description 8
- 238000012258 culturing Methods 0.000 claims abstract description 4
- 239000002904 solvent Substances 0.000 claims abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 235000001014 amino acid Nutrition 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 25
- 239000002243 precursor Substances 0.000 claims description 24
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 23
- 241000588724 Escherichia coli Species 0.000 claims description 21
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 17
- 239000004098 Tetracycline Substances 0.000 claims description 16
- 229960002180 tetracycline Drugs 0.000 claims description 16
- 229930101283 tetracycline Natural products 0.000 claims description 16
- 235000019364 tetracycline Nutrition 0.000 claims description 16
- 150000003522 tetracyclines Chemical class 0.000 claims description 16
- 108020001621 Natriuretic Peptide Proteins 0.000 claims description 13
- 102000004571 Natriuretic peptide Human genes 0.000 claims description 12
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 12
- 239000000692 natriuretic peptide Substances 0.000 claims description 12
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 101800000060 C-type natriuretic peptide Proteins 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 8
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 claims description 7
- 102000055006 Calcitonin Human genes 0.000 claims description 7
- 108060001064 Calcitonin Proteins 0.000 claims description 7
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 7
- 229960004015 calcitonin Drugs 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 6
- 108010091718 peptide L Proteins 0.000 claims description 6
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 5
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 5
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 5
- 230000010261 cell growth Effects 0.000 claims description 5
- 239000000199 parathyroid hormone Substances 0.000 claims description 5
- 229960001319 parathyroid hormone Drugs 0.000 claims description 5
- 101800000457 CNP-22 Proteins 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 210000004898 n-terminal fragment Anatomy 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000002837 heart atrium Anatomy 0.000 claims description 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 239000013612 plasmid Substances 0.000 abstract description 47
- 238000004519 manufacturing process Methods 0.000 abstract description 25
- 125000000539 amino acid group Chemical group 0.000 abstract description 12
- 210000004899 c-terminal region Anatomy 0.000 abstract description 4
- 210000004748 cultured cell Anatomy 0.000 abstract description 2
- 238000000265 homogenisation Methods 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 230000003381 solubilizing effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 108020004414 DNA Proteins 0.000 description 30
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 30
- 229940045644 human calcitonin Drugs 0.000 description 30
- 239000000243 solution Substances 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 27
- 101500025169 Homo sapiens CNP-22 Proteins 0.000 description 26
- 239000000499 gel Substances 0.000 description 24
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 23
- 238000010276 construction Methods 0.000 description 23
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- 239000000872 buffer Substances 0.000 description 19
- 239000007983 Tris buffer Substances 0.000 description 18
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 238000003776 cleavage reaction Methods 0.000 description 14
- 238000001502 gel electrophoresis Methods 0.000 description 14
- 244000005700 microbiome Species 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 13
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
- 108091008146 restriction endonucleases Proteins 0.000 description 12
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 11
- 239000007984 Tris EDTA buffer Substances 0.000 description 11
- 238000001556 precipitation Methods 0.000 description 11
- 238000001962 electrophoresis Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000009395 breeding Methods 0.000 description 9
- 230000001488 breeding effect Effects 0.000 description 9
- 239000013613 expression plasmid Substances 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000007112 amidation reaction Methods 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000009435 amidation Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
- 229960005542 ethidium bromide Drugs 0.000 description 4
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000008049 TAE buffer Substances 0.000 description 3
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000009585 enzyme analysis Methods 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
- SHCMKWXVHLOSIU-UHFFFAOYSA-N 5-hydroxy-7-(4-hydroxy-2,5-dimethoxyphenyl)-2,2-dimethylpyrano[3,2-g]chromen-6-one Chemical compound C1=C(O)C(OC)=CC(C=2C(C3=C(O)C=4C=CC(C)(C)OC=4C=C3OC=2)=O)=C1OC SHCMKWXVHLOSIU-UHFFFAOYSA-N 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101900264058 Escherichia coli Beta-galactosidase Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 239000012722 SDS sample buffer Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000008051 TBE buffer Substances 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 241000269368 Xenopus laevis Species 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 2
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101100113986 Homo sapiens CNP gene Proteins 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- ZJWIXBZTAAJERF-IHRRRGAJSA-N Lys-Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZJWIXBZTAAJERF-IHRRRGAJSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000002862 amidating effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cardiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23076991 | 1991-08-19 | ||
| JP23076991 | 1991-08-19 | ||
| JP22352092 | 1992-07-31 | ||
| JP22352092A JP3531947B2 (ja) | 1991-08-19 | 1992-07-31 | ペプチドの製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69233245D1 DE69233245D1 (de) | 2003-12-11 |
| DE69233245T2 true DE69233245T2 (de) | 2004-04-22 |
Family
ID=26525519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69233245T Expired - Fee Related DE69233245T2 (de) | 1991-08-19 | 1992-08-19 | Verfahren zur Herstellung von Peptiden |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0528686B8 (OSRAM) |
| AT (1) | ATE253639T1 (OSRAM) |
| CA (1) | CA2076320C (OSRAM) |
| DE (1) | DE69233245T2 (OSRAM) |
| ES (1) | ES2206443T3 (OSRAM) |
| HU (1) | HU216335B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037145A (en) | 1994-09-07 | 2000-03-14 | Suntory Limited | Process for production of protein |
| WO1996017942A1 (en) * | 1994-12-07 | 1996-06-13 | Bionebraska, Inc. | Production of peptides using recombinant fusion protein constructs |
| WO1996017941A2 (en) * | 1994-12-07 | 1996-06-13 | Bionebraska, Inc. | Production of c-terminal amidated peptides from recombinant protein constructs |
| BR9608278A (pt) | 1995-04-11 | 1999-10-13 | Merck & Co Inc | Processo para produzir um intermediário de dipeptìdeo de um composto à base de dipeptìdeo |
| IL118473A0 (en) * | 1995-06-02 | 1996-09-12 | Suntory Ltd | Staphylococcus aureus V8 protease genes coding therefor and a method for the production thereof |
| DE19535445A1 (de) * | 1995-09-23 | 1997-03-27 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von natriuretischen Peptiden über Streptavidin-Fusionsproteine |
| EP0861325A1 (de) * | 1995-11-16 | 1998-09-02 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von peptiden über streptavidin-fusionsproteine |
| PT1714972E (pt) * | 1998-07-10 | 2011-12-26 | Scios Inc | Método para a produção de um péptido com um pi acima de 8 ou abaixo de 5 |
| US20020090646A1 (en) * | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
| IL142118A0 (en) * | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| DE60331584D1 (de) | 2002-11-26 | 2010-04-15 | Biocon Ltd | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
| JP4663524B2 (ja) | 2003-09-30 | 2011-04-06 | 第一三共株式会社 | ＯｍｐＴプロテアーゼ変異体を用いたポリペプチドの切断方法 |
| CN118119410A (zh) | 2021-06-02 | 2024-05-31 | Topas医疗科技有限公司 | 包含含有n末端接头的肽的纳米颗粒 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK175535B1 (da) * | 1987-03-04 | 2004-11-29 | Daiichi Suntory Pharma Co Ltd | Fremgangsmåde til fremstilling af et fysiologisk aktivt cysteinholdigt peptid |
-
1992
- 1992-08-12 AT AT92307577T patent/ATE253639T1/de not_active IP Right Cessation
- 1992-08-18 CA CA002076320A patent/CA2076320C/en not_active Expired - Fee Related
- 1992-08-19 ES ES92307577T patent/ES2206443T3/es not_active Expired - Lifetime
- 1992-08-19 HU HU9202688A patent/HU216335B/hu not_active IP Right Cessation
- 1992-08-19 DE DE69233245T patent/DE69233245T2/de not_active Expired - Fee Related
- 1992-08-19 EP EP92307577A patent/EP0528686B8/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| HU216335B (hu) | 1999-06-28 |
| CA2076320C (en) | 2003-10-07 |
| HUT62335A (en) | 1993-04-28 |
| ES2206443T3 (es) | 2004-05-16 |
| EP0528686B1 (en) | 2003-11-05 |
| AU656791B2 (en) | 1995-02-16 |
| EP0528686A3 (OSRAM) | 1994-04-06 |
| DE69233245D1 (de) | 2003-12-11 |
| ATE253639T1 (de) | 2003-11-15 |
| CA2076320A1 (en) | 1993-02-20 |
| AU2107892A (en) | 1993-03-11 |
| EP0528686A2 (en) | 1993-02-24 |
| EP0528686B8 (en) | 2004-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3785864T2 (de) | Verfahren zur Herstellung von menschlichem Epidermalwachstumsfaktor und dessen Analogen. | |
| DE3111405C2 (OSRAM) | ||
| DE68908491T2 (de) | Insulinvorläufer, deren Herstellung und DNA-Sequenzen, Expressionsvehikel und Primer und ein Prozess zur Herstellung von Humaninsulin und Analoge. | |
| DE69021335T2 (de) | Wachstumshormonfusionsproteine. | |
| DE69521752T2 (de) | Verfahren für die Herstellung von Proteinen | |
| DE69030582T2 (de) | Herstellung eines rekombinanten menschlichen interleukin-1-hemmers | |
| DE3486216T2 (de) | Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren. | |
| DE69233008T2 (de) | Fusionierung von Peptiden und Proteinen mit Thioredoxin und thioredoxin-ähnlichen Molekülen | |
| DE69002395T2 (de) | N-terminale Fragmente von menschliches Serumalbumin enthaltenden Fusionsproteinen. | |
| DE3050722C2 (OSRAM) | ||
| DE69128285T2 (de) | Expression rekombinanter polypeptide mit verbesserter möglichkeit zur reinigung | |
| DE69233245T2 (de) | Verfahren zur Herstellung von Peptiden | |
| DE3852706T2 (de) | Verfahren zur Herstellung eines physiologisch aktiven Peptids mit einem Cysteinrest. | |
| DD212982A5 (de) | Verfahren zur herstellung von rinder-wachstumshormon-aehnlichen polypeptiden | |
| EP0211299A2 (de) | Fusionsproteine, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DD154022A5 (de) | Verfahren zur herstellung von menschlichem pre-wachstumshormon | |
| DE69027948T2 (de) | Reinigung von rekombinantem, menschlichem Interleukin-3 | |
| DE69032315T2 (de) | Peptidyl prolyl-cis.trans-isomersae | |
| DE3686365T3 (de) | Herstellungsverfahren für humanes atriales natriuretisches Polypeptid. | |
| DE69732583T2 (de) | Verfahren zur Spaltung eines chimeren Proteins mittels eines 'processing'-Enzyms | |
| DE3751081T2 (de) | [Leu 13] Motilin, dessen kodierende DNS-Moleküle und Verfahren zu dessen Herstellung. | |
| DE68923496T2 (de) | Verfahren zur Herstellung von motilinähnlichen Polypeptiden und seine Expression. | |
| DE3485923T2 (de) | Dna-gen, verfahren zu seiner herstellung und dieses gen enthaltendes plasmid. | |
| DE3687470T2 (de) | Expression in e.coli von hybridpolypeptiden, die die sequenz des wachstumshormons ausloesenden faktors enthalten. | |
| DE69111371T2 (de) | Synthetisches Gen für menschliches Parathyroidhormon. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: DAIICHI ASUBIO PHARMA CO., LTD., TOKIO/TOKYO, JP |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: ASUBIO PHARMA CO., LTD., TOKYO, JP |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |